Back to discover
Disease

Rhinitis

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHRhinitis
3
Publications
24
Clinical trials
3
Related conditions
9
Associated genes
2021
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2027.
  • 2 industry developments reported.
Upcoming Milestones
Clinical Milestones11View all 11
Results expected 2
Recently completed 5
Other updates 1
+3 more in the activity timeline below
Industry & Market2View
Activity timeline13

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Desloratadineapproved

Generic approval — Treatment of allergic rhinitis and urticaria. (2012)

Fluticasone furoateapproved

Original application approval — Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated fo… (2008)

Clinical trials

16 sponsors · 2 new · 5 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT

Phase 2/3 · Recruiting · Lars Olaf Cardell

Prospective, Randomised, DBPC, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma, Allergic to Dpt and/or Df

Phase 3 · Recruiting · Inmunotek S.L.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

Phase 3 · Active, not recruiting · Eli Lilly and Company

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass Pollen

Phase 3 · Recruiting · Inmunotek S.L.

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis Inadequately Controlled by Standard-of-care

Phase 3 · Active, not recruiting · Longbio Pharma

Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice

Phase 4 · Recruiting · Karolinska Institutet
Recruiting

Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT

Phase 2/3 · Recruiting · Lars Olaf Cardell

Prospective, Randomised, DBPC, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma, Allergic to Dpt and/or Df

Phase 3 · Recruiting · Inmunotek S.L.

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass Pollen

Phase 3 · Recruiting · Inmunotek S.L.

Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice

Phase 4 · Recruiting · Karolinska Institutet
Recently completed

A Randomised Double-blind Placebo-controlled Phase III Field Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Chinese Participants Aged 12-65 Years With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma

Phase 3 · Completed · ALK-Abelló A/S

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite

Phase 3 · Completed · HAL Allergy

Short-Term Nasal Decongestant as Bridge Therapy Combined With Intranasal Corticosteroids in Children With Persistent Allergic Rhinitis: A Randomized Controlled Trial

Phase 4 · Completed · Dr. Behcet Uz Children's Hospital

A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)

Phase 4 · Completed · Sanofi

Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine as Treatment in Patients With Allergic Rhinitis

Phase 3 · Completed · Laboratorios Silanes S.A. de C.V.

As Needed Versus Regular Use of Intranasal Corticosteroid in Children With Perennial Allergic Rhinitis: A Randomized Controlled Trial

Phase 3 · Completed · Mahidol University

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2012emaGeneric approval — Desloratadine· Treatment of allergic rhinitis and urticaria. source ↗
2012emaGeneric approval — Desloratadine· Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with: allergic rhinitis chronic idiopathic urticaria as initially diagnosed by a physician source ↗
2011emaGeneric approval — Desloratadine· Dasselta is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria. source ↗
2011emaGeneric approval — Desloratadine· Desloratadine Teva is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria. source ↗
2008emaOriginal application approval — Fluticasone furoate· Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis. source ↗
2001emaOriginal application approval — Desloratadine· Aerius is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria. source ↗
2001emaOriginal application approval — Desloratadine· Neoclarityn is indicated for the relief of symptoms associated with: allergic rhinitis urticaria source ↗
2001emaOriginal application approval — Desloratadine· Azomyr is indicated for the relief of symptoms associated with: allergic rhinitis (see section 5.1) urticaria (see section 5.1) source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2019–2021
Major themes4
  • Delivery of Health Care, Integrated1
  • Rhinitis1
  • Rhinitis, Allergic1
  • Sinusitis1
Leading journals3
  • Allergy1
  • International forum of allergy & rhinology1
  • Rhinology1
Leading researchers8
  • Fokkens WJ3
  • Hopkins C3
  • Mullol J3
  • Bachert C2
  • Bernal-Sprekelsen M2
  • Desrosiers M2
  • Hellings PW2
  • Kern R2
Affiliations (unnormalised)6
  • University Hospitals Leuven3
  • Amsterdam University Medical Centres2
  • Eastern Virginia Medical School2
  • Karolinska Institute2
  • Northwestern University2
  • Nose and Ear Hospital2

Associated genes

9 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

RSPH4A0.37FCER1G0.29RASA20.29TMEM2320.27DOCK100.27ARRDC20.18ITPKA0.09RTF10.05TTLL100.03

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Sinusitis3Chronic Disease2Nasal Polyps2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.

Identifiers
MeSHRhinitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.